{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T10:09:52Z","timestamp":1779271792156,"version":"3.51.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100012051","name":"Lupus Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012051","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"DFG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008454","name":"Boehringer Ingelheim Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008454","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.kint.2026.03.010","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T09:18:27Z","timestamp":1779268707000},"page":"1081-1084","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["T-cell engagers mediate deep cell depletion beyond autoimmunity"],"prefix":"10.1016","volume":"109","author":[{"given":"Johanna T.","family":"Kurzhagen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Laqua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8414-1470","authenticated-orcid":false,"given":"Mario","family":"Schiffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2873-5135","authenticated-orcid":false,"given":"Ricardo","family":"Grieshaber-Bouyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2026.03.010_bib1","article-title":"From promise to practice: evaluating the clinical impact of FcRn inhibition in IgG-mediated autoimmune rheumatic diseases","volume":"16","author":"Yang","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2026.03.010_bib2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJM199003153221102","article-title":"Impaired function of macrophage Fc gamma receptors in end-stage renal disease","volume":"322","author":"Ruiz","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.03.010_bib3","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1586\/14787210.2015.1079127","article-title":"Fc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseases","volume":"13","author":"Chan","year":"2015","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.kint.2026.03.010_bib4","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2026.03.010_bib5","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","article-title":"Bispecific T cell engager therapy for refractory rheumatoid arthritis","volume":"30","author":"Bucci","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2026.03.010_bib6","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJMc2408786","article-title":"BCMA-targeted T-cell\u2013engager therapy for autoimmune disease","volume":"391","author":"Hagen","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.03.010_bib7","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1056\/NEJMc2407150","article-title":"Teclistamab-induced remission in refractory systemic lupus erythematosus","volume":"391","author":"Alexander","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.03.010_bib8","doi-asserted-by":"crossref","first-page":"114071","DOI":"10.1016\/j.ejca.2024.114071","article-title":"Application of blinatumomab, a bispecific anti-CD3\/CD19 T-cell engager, in treating severe systemic sclerosis: A case study","volume":"204","author":"Subklewe","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.kint.2026.03.010_bib9","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ard.2025.01.043","article-title":"Teclistamab in relapsed systemic sclerosis after autologous haematopoietic stem cell transplantation","volume":"84","author":"Siegert","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2026.03.010_bib10","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.ard.2025.05.007","article-title":"One-year remission of therapy-resistant SLE after a single course with the bispecific CD3: BCMA antibody teclistamab, but induction of a non-infectious Crohn\u2019s-like inflammatory bowel disease","volume":"84","author":"Lorenz","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2026.03.010_bib11","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1056\/NEJMc2502297","article-title":"BCMA-gargeted T-cell engager for autoimmune hemolytic anemia after CD19 CAR T-cell therapy","volume":"392","author":"Zhang","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.03.010_bib12","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMc2506740","article-title":"BCMA T-cell engager therapy in patients with refractory autoimmune disease","volume":"393","author":"Bucci","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.03.010_bib13","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1016\/j.ymthe.2025.06.042","article-title":"CD19xCD3 T cell engager blinatumomab effective in refractory generalized myasthenic syndromes","volume":"33","author":"Ruck","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.kint.2026.03.010_bib14","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1016\/j.ymthe.2025.06.029","article-title":"Effective use of BCMA-targeting bispecific T cell-engaging antibody in treatment-refractory LRP4+ myasthenia gravis","volume":"33","author":"Schreiber","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.kint.2026.03.010_bib15","doi-asserted-by":"crossref","unstructured":"Stutz AN, Lahu LM, Jaschinski S, et al. Mosunetuzumab, a CD20xCD3 bispecific T-cell engager, in granulomatosis with polyangiitis. Ann Rheum Dis. Published online November 20, 2025. https:\/\/doi.org\/10.1016\/j.ymthe.2025.06.029","DOI":"10.1016\/j.ard.2025.10.026"},{"key":"10.1016\/j.kint.2026.03.010_bib16","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0140-6736(25)02515-2","article-title":"BCMA-CD3 T-cell engager as salvage therapy for multirefractory primary immune thrombocytopenia","volume":"407","author":"Duque-Afonso","year":"2026","journal-title":"The Lancet"},{"key":"10.1016\/j.kint.2026.03.010_bib17","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.kint.2026.01.020","article-title":"B-cell maturation antigen-Targeted T-cell Engager Therapy Combined with B-cell Depletion for Treatment of Refractory HLA Sensitization","volume":"109","author":"Leon","year":"2026","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.03.010_bib18","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1016\/j.ekir.2024.08.020","article-title":"Open-label phase 1\/2 study of daratumumab-based desensitization before kidney transplantation","volume":"9","author":"Pilon","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.03.010_bib19","doi-asserted-by":"crossref","first-page":"e20251652","DOI":"10.1084\/jem.20251652","article-title":"T cell engagers emerge as a compelling therapeutic modality","volume":"223","author":"Baeuerle","year":"2026","journal-title":"J Exp Med"},{"key":"10.1016\/j.kint.2026.03.010_bib20","article-title":"CAR-T Therapy Targeting CD19 and BCMA in Highly Sensitized Kidney Transplant Participants","year":"2026","journal-title":"ClinicalTrials.gov Identifier: NCT07350837. Updated April 16, 2026"},{"key":"10.1016\/j.kint.2026.03.010_bib21","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1016\/j.immuni.2025.10.006","article-title":"Long-lived IgE plasma cells persist in secondary lymphoid tissues using a navitoclax-sensitive survival program","volume":"58","author":"Ding","year":"2025","journal-title":"Immunity"},{"key":"10.1016\/j.kint.2026.03.010_bib22","article-title":"Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy","year":"2026","journal-title":"ClinicalTrials.gov Identifier: NCT06369467. Updated April 16, 2026"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826002449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826002449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T09:51:18Z","timestamp":1779270678000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253826002449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0085253826002449"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2026.03.010","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"T-cell engagers mediate deep cell depletion beyond autoimmunity","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.01.020","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society of Nephrology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}